Associate Professor
Stanford University School of Medicine
Stanford, California
Dr. Muharrem Yunce grew up in Diyarbakir, Turkey, and received his medical degree from Dicle University. He completed his internal medicine residency training at MedStar Health in Baltimore, affiliated with Georgetown University, and then pursued his fellowship in blood banking & transfusion medicine at Stanford University.
Dr. Yunce currently serves as the Medical Director of Therapeutic Apheresis for Stanford Health Care and is a Clinical Associate Professor of Pathology at Stanford University School of Medicine. He oversees the application of therapeutic apheresis in various disease processes. He actively teaches transfusion medicine fellows and pathology residents. In recognition of his dedication to education, he was selected for the prestigious Stanford Pathology Teaching Award in 2023.
In addition to his clinical and teaching responsibilities, he is interested in exploring the potential role of therapeutic plasma exchange (TPE) in immune checkpoint inhibitor toxicity as well as its role in solid organ transplant rejection.
Dr. Yunce is a member of multiple national associations, including the American Society for Apheresis (ASFA) and the Association for the Advancement of Blood & Biotherapies. He is also the chair of the TPE in Solid Organ Transplantation Committee.
Outside of work, Dr. Yunce enjoys spending time with his family and exploring different hiking trails around the Bay Area.
Dr. Yunce is also a well-recognized teaching faculty member in the Department of Pathology. He was honored with the Teaching Award in 2023 by the department and was nominated in 2023 and 2024 for the prestigious Alwin C. Rambar-James B.D. Mark Award for Excellence in Patient Care.
As an active member of the American Society of Apheresis, Dr. Yunce chairs the research subcommittee on TPE utilization in solid organ transplant rejection and desensitization protocols as well as member of multiple research subcommittees.
Disclosure information not submitted.
AM25-SN-23-L - FcRN Inhibitors – a New Era for Transfusion Medicine?
Sunday, October 26, 2025
3:45 PM - 4:45 PM PT